Intrinsic value of DexCom - DXCM

Previous Close

$44.78

  Intrinsic Value

$0.79

stock screener

  Rating & Target

str. sell

-98%

Previous close

$44.78

 
Intrinsic value

$0.79

 
Up/down potential

-98%

 
Rating

str. sell

We calculate the intrinsic value of DXCM stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 3.9

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  42.54
  24.80
  22.82
  21.04
  19.43
  17.99
  16.69
  15.52
  14.47
  13.52
  12.67
  11.90
  11.21
  10.59
  10.03
  9.53
  9.08
  8.67
  8.30
  7.97
  7.67
  7.41
  7.17
  6.95
  6.75
  6.58
  6.42
  6.28
  6.15
  6.04
  5.93
Revenue, $m
  573
  715
  878
  1,063
  1,270
  1,498
  1,748
  2,019
  2,312
  2,624
  2,957
  3,309
  3,680
  4,070
  4,478
  4,905
  5,350
  5,814
  6,296
  6,798
  7,320
  7,862
  8,426
  9,011
  9,620
  10,253
  10,911
  11,596
  12,310
  13,053
  13,827
Variable operating expenses, $m
 
  743
  913
  1,105
  1,319
  1,556
  1,816
  2,098
  2,401
  2,725
  3,071
  3,435
  3,820
  4,225
  4,648
  5,091
  5,554
  6,035
  6,536
  7,057
  7,599
  8,162
  8,747
  9,354
  9,986
  10,643
  11,327
  12,038
  12,778
  13,550
  14,354
Fixed operating expenses, $m
 
  43
  44
  45
  46
  48
  49
  50
  51
  52
  54
  55
  56
  58
  59
  61
  62
  64
  66
  67
  69
  71
  72
  74
  76
  78
  80
  82
  84
  86
  88
Total operating expenses, $m
  637
  786
  957
  1,150
  1,365
  1,604
  1,865
  2,148
  2,452
  2,777
  3,125
  3,490
  3,876
  4,283
  4,707
  5,152
  5,616
  6,099
  6,602
  7,124
  7,668
  8,233
  8,819
  9,428
  10,062
  10,721
  11,407
  12,120
  12,862
  13,636
  14,442
Operating income, $m
  -64
  -71
  -79
  -87
  -96
  -106
  -116
  -128
  -140
  -153
  -167
  -181
  -197
  -213
  -230
  -248
  -266
  -285
  -305
  -326
  -348
  -370
  -393
  -417
  -442
  -468
  -495
  -523
  -553
  -583
  -615
EBITDA, $m
  -49
  -53
  -57
  -60
  -64
  -69
  -73
  -78
  -84
  -90
  -96
  -102
  -109
  -115
  -123
  -130
  -138
  -146
  -155
  -163
  -172
  -182
  -191
  -202
  -212
  -223
  -234
  -246
  -258
  -271
  -284
Interest expense (income), $m
  0
  0
  1
  2
  4
  5
  7
  9
  11
  13
  15
  17
  20
  23
  25
  28
  32
  35
  38
  42
  45
  49
  53
  57
  61
  66
  70
  75
  80
  85
  91
Earnings before tax, $m
  -65
  -71
  -80
  -89
  -99
  -111
  -123
  -136
  -151
  -166
  -182
  -198
  -217
  -235
  -255
  -276
  -298
  -320
  -343
  -368
  -393
  -419
  -446
  -474
  -504
  -534
  -566
  -599
  -633
  -668
  -705
Tax expense, $m
  1
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -66
  -71
  -80
  -89
  -99
  -111
  -123
  -136
  -151
  -166
  -182
  -198
  -217
  -235
  -255
  -276
  -298
  -320
  -343
  -368
  -393
  -419
  -446
  -474
  -504
  -534
  -566
  -599
  -633
  -668
  -705

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  124
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  403
  348
  428
  518
  618
  729
  851
  983
  1,125
  1,278
  1,440
  1,611
  1,792
  1,981
  2,180
  2,388
  2,605
  2,830
  3,065
  3,310
  3,564
  3,828
  4,102
  4,387
  4,684
  4,992
  5,312
  5,646
  5,993
  6,355
  6,732
Adjusted assets (=assets-cash), $m
  279
  348
  428
  518
  618
  729
  851
  983
  1,125
  1,278
  1,440
  1,611
  1,792
  1,981
  2,180
  2,388
  2,605
  2,830
  3,065
  3,310
  3,564
  3,828
  4,102
  4,387
  4,684
  4,992
  5,312
  5,646
  5,993
  6,355
  6,732
Revenue / Adjusted assets
  2.054
  2.055
  2.051
  2.052
  2.055
  2.055
  2.054
  2.054
  2.055
  2.053
  2.053
  2.054
  2.054
  2.055
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
Average production assets, $m
  84
  104
  128
  155
  185
  219
  255
  295
  338
  383
  432
  483
  537
  594
  654
  716
  781
  849
  919
  993
  1,069
  1,148
  1,230
  1,316
  1,405
  1,497
  1,593
  1,693
  1,797
  1,906
  2,019
Working capital, $m
  178
  67
  83
  100
  119
  141
  164
  190
  217
  247
  278
  311
  346
  383
  421
  461
  503
  546
  592
  639
  688
  739
  792
  847
  904
  964
  1,026
  1,090
  1,157
  1,227
  1,300
Total debt, $m
  0
  30
  64
  102
  145
  192
  244
  301
  362
  427
  496
  569
  646
  727
  812
  901
  993
  1,090
  1,190
  1,294
  1,403
  1,515
  1,633
  1,754
  1,881
  2,012
  2,149
  2,292
  2,440
  2,595
  2,755
Total liabilities, $m
  119
  149
  183
  221
  264
  311
  363
  420
  481
  546
  615
  688
  765
  846
  931
  1,020
  1,112
  1,209
  1,309
  1,413
  1,522
  1,634
  1,752
  1,873
  2,000
  2,131
  2,268
  2,411
  2,559
  2,714
  2,874
Total equity, $m
  284
  199
  245
  297
  354
  418
  488
  563
  645
  732
  825
  923
  1,027
  1,135
  1,249
  1,368
  1,492
  1,622
  1,756
  1,896
  2,042
  2,193
  2,350
  2,514
  2,684
  2,860
  3,044
  3,235
  3,434
  3,641
  3,857
Total liabilities and equity, $m
  403
  348
  428
  518
  618
  729
  851
  983
  1,126
  1,278
  1,440
  1,611
  1,792
  1,981
  2,180
  2,388
  2,604
  2,831
  3,065
  3,309
  3,564
  3,827
  4,102
  4,387
  4,684
  4,991
  5,312
  5,646
  5,993
  6,355
  6,731
Debt-to-equity ratio
  0.000
  0.150
  0.260
  0.340
  0.410
  0.460
  0.500
  0.530
  0.560
  0.580
  0.600
  0.620
  0.630
  0.640
  0.650
  0.660
  0.670
  0.670
  0.680
  0.680
  0.690
  0.690
  0.690
  0.700
  0.700
  0.700
  0.710
  0.710
  0.710
  0.710
  0.710
Adjusted equity ratio
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -66
  -71
  -80
  -89
  -99
  -111
  -123
  -136
  -151
  -166
  -182
  -198
  -217
  -235
  -255
  -276
  -298
  -320
  -343
  -368
  -393
  -419
  -446
  -474
  -504
  -534
  -566
  -599
  -633
  -668
  -705
Depreciation, amort., depletion, $m
  15
  18
  22
  27
  31
  37
  43
  49
  56
  64
  72
  79
  88
  97
  107
  117
  128
  139
  151
  163
  175
  188
  202
  216
  230
  245
  261
  278
  295
  312
  331
Funds from operations, $m
  50
  -53
  -58
  -62
  -68
  -74
  -80
  -87
  -94
  -102
  -111
  -119
  -128
  -138
  -148
  -159
  -170
  -181
  -193
  -205
  -218
  -231
  -245
  -259
  -273
  -289
  -305
  -321
  -338
  -356
  -375
Change in working capital, $m
  -6
  13
  15
  17
  19
  21
  24
  26
  27
  29
  31
  33
  35
  37
  38
  40
  42
  44
  45
  47
  49
  51
  53
  55
  57
  59
  62
  64
  67
  70
  73
Cash from operations, $m
  56
  -67
  -73
  -80
  -87
  -95
  -104
  -113
  -122
  -132
  -142
  -152
  -163
  -175
  -187
  -199
  -211
  -225
  -238
  -252
  -267
  -282
  -297
  -314
  -331
  -348
  -366
  -385
  -405
  -426
  -447
Maintenance CAPEX, $m
  0
  -14
  -17
  -21
  -25
  -30
  -36
  -42
  -48
  -55
  -63
  -71
  -79
  -88
  -97
  -107
  -117
  -128
  -139
  -151
  -163
  -175
  -188
  -202
  -216
  -230
  -245
  -261
  -278
  -295
  -312
New CAPEX, $m
  -56
  -21
  -24
  -27
  -30
  -33
  -37
  -40
  -43
  -46
  -49
  -51
  -54
  -57
  -60
  -62
  -65
  -68
  -70
  -73
  -76
  -79
  -82
  -85
  -89
  -92
  -96
  -100
  -104
  -108
  -113
Cash from investing activities, $m
  -56
  -35
  -41
  -48
  -55
  -63
  -73
  -82
  -91
  -101
  -112
  -122
  -133
  -145
  -157
  -169
  -182
  -196
  -209
  -224
  -239
  -254
  -270
  -287
  -305
  -322
  -341
  -361
  -382
  -403
  -425
Free cash flow, $m
  0
  -101
  -114
  -128
  -143
  -159
  -176
  -194
  -213
  -233
  -253
  -275
  -297
  -320
  -344
  -368
  -394
  -420
  -448
  -476
  -506
  -536
  -568
  -601
  -635
  -671
  -708
  -747
  -787
  -829
  -873
Issuance/(repayment) of debt, $m
  -2
  30
  34
  38
  43
  47
  52
  56
  61
  65
  69
  73
  77
  81
  85
  89
  93
  96
  100
  104
  108
  113
  117
  122
  127
  132
  137
  142
  148
  154
  161
Issuance/(repurchase) of shares, $m
  10
  111
  125
  141
  157
  174
  193
  212
  232
  253
  275
  297
  320
  344
  369
  395
  422
  449
  478
  508
  538
  570
  603
  638
  674
  711
  749
  790
  832
  876
  921
Cash from financing (excl. dividends), $m  
  8
  141
  159
  179
  200
  221
  245
  268
  293
  318
  344
  370
  397
  425
  454
  484
  515
  545
  578
  612
  646
  683
  720
  760
  801
  843
  886
  932
  980
  1,030
  1,082
Total cash flow (excl. dividends), $m
  8
  39
  45
  51
  57
  63
  69
  75
  80
  86
  91
  95
  100
  106
  111
  116
  121
  126
  131
  136
  141
  147
  153
  159
  165
  171
  178
  186
  193
  201
  210
Retained Cash Flow (-), $m
  -63
  -111
  -125
  -141
  -157
  -174
  -193
  -212
  -232
  -253
  -275
  -297
  -320
  -344
  -369
  -395
  -422
  -449
  -478
  -508
  -538
  -570
  -603
  -638
  -674
  -711
  -749
  -790
  -832
  -876
  -921
Prev. year cash balance distribution, $m
 
  124
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  53
  -80
  -89
  -100
  -112
  -124
  -138
  -152
  -168
  -184
  -201
  -220
  -239
  -259
  -280
  -301
  -324
  -347
  -372
  -397
  -423
  -451
  -479
  -509
  -539
  -571
  -604
  -639
  -674
  -712
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  50
  -73
  -78
  -82
  -86
  -90
  -93
  -95
  -96
  -96
  -96
  -94
  -91
  -87
  -82
  -77
  -70
  -64
  -57
  -50
  -44
  -37
  -31
  -26
  -21
  -17
  -13
  -10
  -7
  -5
Current shareholders' claim on cash, %
  100
  93.5
  88.0
  83.2
  79.0
  75.3
  72.0
  69.0
  66.3
  63.8
  61.5
  59.3
  57.3
  55.5
  53.7
  52.1
  50.5
  49.0
  47.6
  46.3
  45.0
  43.8
  42.6
  41.5
  40.4
  39.4
  38.4
  37.4
  36.5
  35.6
  34.7

Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company's markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient's receiver and an application on the patient's iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).

FINANCIAL RATIOS  of  DexCom (DXCM)

Valuation Ratios
P/E Ratio -57.4
Price to Sales 6.6
Price to Book 13.3
Price to Tangible Book
Price to Cash Flow 67.6
Price to Free Cash Flow 0
Growth Rates
Sales Growth Rate 42.5%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 69.7%
Cap. Spend. - 3 Yr. Gr. Rate 47.6%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -19%
Ret/ On Assets - 3 Yr. Avg. -19.2%
Return On Total Capital -26%
Ret/ On T. Cap. - 3 Yr. Avg. -25.4%
Return On Equity -26.1%
Return On Equity - 3 Yr. Avg. -26%
Asset Turnover 1.6
Profitability Ratios
Gross Margin 66%
Gross Margin - 3 Yr. Avg. 67.7%
EBITDA Margin -8.7%
EBITDA Margin - 3 Yr. Avg. -8.6%
Operating Margin -11.2%
Oper. Margin - 3 Yr. Avg. -11.3%
Pre-Tax Margin -11.3%
Pre-Tax Margin - 3 Yr. Avg. -11.4%
Net Profit Margin -11.5%
Net Profit Margin - 3 Yr. Avg. -11.5%
Effective Tax Rate -1.5%
Eff/ Tax Rate - 3 Yr. Avg. -0.5%
Payout Ratio 0%

DXCM stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the DXCM stock intrinsic value calculation we used $573 million for the last fiscal year's total revenue generated by DexCom. The default revenue input number comes from 2016 income statement of DexCom. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our DXCM stock valuation model: a) initial revenue growth rate of 24.8% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for DXCM is calculated based on our internal credit rating of DexCom, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of DexCom.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of DXCM stock the variable cost ratio is equal to 104%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $42 million in the base year in the intrinsic value calculation for DXCM stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for DexCom.

Corporate tax rate of 27% is the nominal tax rate for DexCom. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the DXCM stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for DXCM are equal to 14.6%.

Life of production assets of 6.1 years is the average useful life of capital assets used in DexCom operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for DXCM is equal to 9.4%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $284 million for DexCom - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 86.646 million for DexCom is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of DexCom at the current share price and the inputted number of shares is $3.9 billion.

RELATED COMPANIES Price Int.Val. Rating
JNJ Johnson&Johnso 142.40 147.16  hold
ABT Abbott Laborat 56.32 404.36  str.buy
WST West Pharmaceu 93.84 30.52  str.sell
CAH Cardinal Healt 66.71 157.03  str.buy

COMPANY NEWS

▶ DexCom Announces Upcoming Conference Presentation   [Oct-19-17 08:30AM  Business Wire]
▶ ETFs with exposure to DexCom, Inc. : October 17, 2017   [Oct-17-17 09:40AM  Capital Cube]
▶ DexCom's Quiet Consolidation After Huge Decline   [Oct-09-17 01:26PM  Benzinga]
▶ ETFs with exposure to DexCom, Inc. : October 6, 2017   [Oct-06-17 10:46AM  Capital Cube]
▶ 5 Top Stocks for October   [Oct-04-17 08:45PM  Motley Fool]
▶ What Happened in the Stock Market Today   [Sep-28-17 05:00PM  Motley Fool]
▶ Why DexCom Stock Is Getting Crushed Today   [11:53AM  Motley Fool]
▶ DexCom: Stay Sweet or Go Sour?   [11:00AM  Barrons.com]
▶ Fitbit Stock Briefly Touches New Highs   [10:59AM  Investopedia]
▶ Fitbit Inc (FIT) Stock Looks Good for the Very Short Term   [Sep-26-17 07:18AM  InvestorPlace]
▶ Fitbit Stock Tests Support After Breakout Fizzles   [Sep-20-17 01:06PM  Investopedia]
▶ Fitbit Inc (NYSE:FIT) Stock Still Has A Lot of Work To Do   [Sep-19-17 09:14AM  InvestorPlace]
▶ DexCom Announces Upcoming Conference Presentation   [Sep-08-17 05:22PM  Business Wire]
▶ Why Fitbit Stock Is Soaring Today   [12:37PM  Motley Fool]
▶ DexCom (DXCM) in Focus: Stock Moves 6.7% Higher   [Aug-03-17 08:44AM  Zacks]
▶ DexCom beats Street 2Q forecasts   [Aug-01-17 10:05PM  Associated Press]
▶ ETFs with exposure to DexCom, Inc. : July 24, 2017   [Jul-24-17 03:30PM  Capital Cube]
▶ ETFs with exposure to DexCom, Inc. : July 14, 2017   [Jul-14-17 02:03PM  Capital Cube]
▶ DexCom Announces Upcoming Conference Presentation   [Jul-07-17 08:00AM  Business Wire]
▶ DexCom, Inc. Value Analysis (NASDAQ:DXCM) : July 5, 2017   [Jul-05-17 01:28PM  Capital Cube]
▶ 3 Growth Stocks for Ambitious Investors   [Jun-09-17 01:27PM  Motley Fool]
▶ Company News for June 06, 2017   [Jun-06-17 10:04AM  Zacks]
▶ ETFs with exposure to DexCom, Inc. : May 29, 2017   [May-29-17 12:45PM  Capital Cube]
▶ ETFs with exposure to DexCom, Inc. : May 18, 2017   [May-18-17 01:40PM  Capital Cube]
▶ Will Wearable Technology Make Us Healthier?   [May-16-17 09:03AM  Motley Fool]
▶ ETFs with exposure to DexCom, Inc. : May 5, 2017   [May-05-17 04:05PM  Capital Cube]
▶ DexCom, Inc. Value Analysis (NASDAQ:DXCM) : May 3, 2017   [May-03-17 04:41PM  Capital Cube]
▶ Here's Why DexCom Stock Is Tanking Today   [12:40PM  Motley Fool]
▶ DexCom reports 1Q loss   [May-02-17 05:12PM  Associated Press]
▶ Sohn Investment Conference: Investing for good   [Apr-24-17 12:47PM  CNBC Videos]
Financial statements of DXCM
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.